A new study reveals that publicly traded health companies have funneled $2.6 trillion to shareholders over two decades, even as consumers struggle with soaring medical costs. In 2022 alone, these companies paid $170 billion in dividends and stock buybacks, a 315% increase from 2001.
Nineteen companies, led by Pfizer, Johnson & Johnson, and UnitedHealth, accounted for 80% of payouts. Researchers suggest rising drug prices and insurance premiums fuel these profits, often at the expense of consumers. Critics argue that heavy regulation and lack of competition distort the market.
As taxpayers fund much of U.S. health care through Medicare, Medicaid, and tax breaks, experts question whether these profits are justified. Some call for increased oversight, while others defend shareholder returns as part of a functioning market.
FingerLakes1.com is the region’s leading all-digital news publication. The company was founded in 1998 and has been keeping residents informed for more than two decades. Have a lead? Send it to news@fingerlakes1.com.
